Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium + olodaterol
Drug: Placebo

First Posted Date: 2020-01-10

Last Posted Date: 2021-11-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 213

Registration Number: NCT04223843

Locations: 🇺🇸
Meris Clinical Research, Brandon, Florida, United States
🇺🇸
Clinical Research Specialists LLC, Kissimmee, Florida, United States
🇩🇪
Klinische Forschung Berlin GbR, Berlin, Germany

and more 22 locations

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Interventions: Drug: Afatinib

First Posted Date: 2019-12-20

Last Posted Date: 2025-02-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT04206787

Locations: 🇨🇳
West China Hospital, Chengdu, China
🇨🇳
Hainan Cancer Hospital, Haikou, China
🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 7 locations

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 474121 oral solution
Drug: BI 474121 tablet
Drug: Placebo tablet
Drug: Placebo solution

First Posted Date: 2019-12-11

Last Posted Date: 2024-03-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT04194645

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium and Olodaterol (Tio+Olo)
Drug: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)

First Posted Date: 2019-12-03

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27190

Registration Number: NCT04184297

Locations: 🇺🇸
HealthCore, Inc., Andover, Massachusetts, United States

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Acarbose
Drug: Linagliptin

First Posted Date: 2019-11-29

Last Posted Date: 2022-06-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 85

Registration Number: NCT04180813

Locations: 🇨🇳
Huai'an first people's hospital, Huai'an, China
🇨🇳
Dongying People's Hospital, Dongying, China
🇨🇳
Zhongda Hospital Southeast University, Nanjing, China

and more 7 locations

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Completed

Conditions: Non-squamous, Non-Small Cell Lung Cancer

Interventions: Drug: Afatinib (Gi(l)otrif®)
Drug: Erlotinib (Tarceva®)
Drug: Osimertinib (Tagrisso®)
Drug: Gefitinib (IRESSA®)

First Posted Date: 2019-11-27

Last Posted Date: 2023-05-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 462

Registration Number: NCT04179890

Locations: 🇬🇧
Royal Marsden Hospital, London, United Kingdom

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Phase 1

Completed

Conditions: Healthy
Chronic Kidney Disease

Interventions: Drug: BI 764198

First Posted Date: 2019-11-25

Last Posted Date: 2020-12-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT04176536

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Long-acting Muscarinic Antagonists (LAMA)
Drug: Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)

First Posted Date: 2019-11-21

Last Posted Date: 2022-04-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9284

Registration Number: NCT04172701

Locations: 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Empagliflozin
Drug: Placebo to Empagliflozin

First Posted Date: 2019-11-08

Last Posted Date: 2022-07-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 530

Registration Number: NCT04157751

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

and more 115 locations

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 456906
Drug: Placebo
Drug: Semaglutide

First Posted Date: 2019-11-06

Last Posted Date: 2022-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 413

Registration Number: NCT04153929

Locations: 🇺🇸
Javara Research, Sugar Land, Texas, United States
🇺🇸
San Marcus Research Clinic, Inc., Miami, Florida, United States
🇬🇧
Burbage Surgery, Burbage, Hinkley, United Kingdom

and more 74 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy